Comprehensive analysis of therapeutic peptides — their biological mechanisms, clinical evidence, and physiological effects. For research and educational purposes.
BPC-157 and TB-500 are synthetic peptides recognized for their regenerative capabilities. While often researched together for synergistic effects, they possess distinct origins and primary mechanisms of action. Neither peptide is approved for human therapeutic use by the FDA, and both are prohibited by WADA.
BPC-157 is a synthetic 15-amino-acid peptide derived from a protective protein in human gastric juice. It supports tissue repair and angiogenesis by activating the FAK-paxillin pathway (fibroblast activity / collagen formation) and the VEGFR2-Akt-eNOS pathway (nitric oxide production / improved blood flow). It also increases growth hormone receptor expression in tendon fibroblasts.
TB-500 is a synthetic fragment of Thymosin Beta-4, corresponding to its actin-binding region. By binding to G-actin, TB-500 facilitates cell migration to injury sites — enabling endothelial cells to form new blood vessels and supporting broad, systemic tissue regeneration.
BPC-157 has demonstrated significant efficacy in animal studies for supporting the repair of transected tendons, ligaments, muscles, skin, and bone. It exhibits strong gastrointestinal protective effects, and is in clinical trials for inflammatory bowel disease. Animal models suggest neuroprotective effects.
TB-500 research highlights its role in driving cell migration and new vessel growth. It upregulates VEGF and engages pathways related to cell survival and matrix remodeling — suited for "whole-tissue" recovery.
BPC-157 is associated with localized repair — strong preclinical evidence for tendon/ligament repair and potent gastrointestinal protective effects.
TB-500 is more systemic. Its actin regulation and cell migration promotion makes it suitable for broad tissue regeneration and improved vascularization across multiple tissue types simultaneously.
CJC-1295 and Ipamorelin are growth hormone secretagogues — synthetic peptides that stimulate the body's own production of growth hormone (GH). Used in combination for a synergistic effect. Neither is FDA-approved for anti-aging or performance enhancement; both are WADA-prohibited.
CJC-1295 is a GHRH analog that binds to pituitary GHRH receptors. The DAC version has a 6–8 day half-life for sustained GH/IGF-1 elevation. The non-DAC version (Mod GRF 1-29) has a ~30min half-life for natural pulsatile GH release.
Ipamorelin is a selective ghrelin mimetic (GHRP) with ~2hr half-life. Highly selective — stimulates GH without significantly affecting cortisol or prolactin. Together, CJC-1295 provides steady elevated GH baseline while Ipamorelin induces sharp pulses.
A 2006 clinical trial showed CJC-1295 with DAC produced sustained GH increases (2–10× for 6+ days) and IGF-1 increases (1.5–3× for 9–11 days) from a single injection. Ipamorelin trials confirmed biologically effective GH secretion within 1 hour.
Combining GHRH analog + GHRP shows supra-additive GH release. Research in aged rats showed significant increases in bone mineral content and lean mass over 12 weeks.
Elevated GH and IGF-1 are associated with increased protein synthesis, lipolysis, and cellular replication — supporting muscle growth, fat loss, and injury recovery. Higher GHRH activity is linked to increased slow-wave sleep, essential for muscle repair.
Potential risks include injection site reactions, water retention, and flu-like symptoms. Contraindicated for active cancer diagnosis.
Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed based on epithalamin, a natural peptide extract from the pineal gland. Primarily researched for its potential geroprotective (anti-aging) effects through telomerase activation.
The primary mechanism is telomerase activation, which lengthens telomeres — the protective chromosome caps that shorten with each cell division. By restoring telomere length, Epithalon may delay cellular senescence.
Additional pathways include epigenetic regulation (chromatin structure and gene expression), circadian rhythm restoration via melatonin synthesis, and strengthened antioxidant defenses.
A long-term human study on elderly subjects reported a 1.6–1.8× decrease in mortality rates over several years. A 15-year follow-up continued to show significantly lower mortality.
In cell culture, Epithalon activated telomerase and elongated telomeres in human fibroblast cells, overcoming cellular senescence. Animal studies demonstrated restored melatonin production in aged monkeys.
Epithalon's primary impact is counteracting age-related decline at a cellular level. By lengthening telomeres, regulating gene expression, and restoring circadian rhythms, it may help maintain more youthful biological function.
Its melatonin-boosting ability may improve sleep quality. Reported to be well-tolerated with no severe adverse effects in clinical trials.
GHK-Cu is a naturally occurring copper-peptide complex (glycyl-L-histidyl-L-lysine + Cu²⁺). Its concentration in human plasma declines significantly with age. Widely researched for tissue repair, skin regeneration, and anti-inflammatory processes.
A master signaling peptide that modulates the expression of thousands of human genes. Stimulates both synthesis and breakdown of extracellular matrix (collagen, glycosaminoglycans). Promotes angiogenesis via VEGF and bFGF.
Potent anti-inflammatory (suppresses TNF-α, IL-6) and antioxidant effects. Regulates the SIRT1/STAT3 signaling pathway, reducing inflammation and promoting cellular barrier integrity.
In wound models: promoted wound contraction, accelerated new tissue formation, increased antioxidant enzyme activity. In colitis models: alleviated symptoms by upregulating SIRT1 and restoring epithelial barrier integrity.
Human clinical research shows topical GHK-Cu improves skin density, thickness, and firmness while reducing fine lines. Plasma levels drop from ~200ng/ml at age 20 to ~80ng/ml by age 60.
Most widely used in cosmetic and dermatological products for anti-aging and skin rejuvenation. Stimulates collagen production, improves elasticity, and reduces inflammation.
Potent tissue-repair and anti-inflammatory properties make it a subject of research for broad regenerative applications. Its gene-modulating capacity suggests systemic benefits for tissue health.
Glutathione (GSH) is a tripeptide (glutamate, cysteine, glycine) synthesized in every cell. Often called the body's "master antioxidant" due to its central role in protecting cells from damage and detoxifying harmful substances.
Antioxidant Defense: Directly neutralizes reactive oxygen species (ROS). Key component of the glutathione peroxidase enzyme system. The GSH/GSSG ratio is a critical indicator of cellular oxidative stress.
Detoxification: Via Phase II conjugation through GSTs, binds toxins, drugs, pollutants, and carcinogens — making them water-soluble for excretion. Critical for detoxifying heavy metals and persistent organic pollutants.
Low GSH levels are implicated in neurodegenerative disorders, liver disease, cardiovascular disease, diabetes, and certain cancers. Over 40 clinical trials listed in DrugBank.
Direct oral supplementation shows poor bioavailability. More effective clinical strategy: provide precursors like NAC, which rapidly replenishes liver glutathione stores.
Indispensable for cellular health, oxidative damage protection, and toxin clearance. Synthesis depends on amino acid availability — cysteine is the rate-limiting factor.
Levels are depleted by poor nutrition, environmental toxins, stress, and aging. Supported by sulfur-rich diets, reduced toxicant exposure, and precursors like NAC or whey protein.
Human Chorionic Gonadotropin (HCG) is a glycoprotein hormone structurally similar to LH. It plays a critical role in reproductive health in both sexes. FDA-approved for specific medical uses but not approved for weight loss.
Mimics LH by binding to its receptor. In men: activates Leydig cells to produce testosterone, essential for spermatogenesis. In women: triggers egg maturation, induces ovulation, and supports the corpus luteum's progesterone production.
FDA-approved for female infertility (~30% pregnancy rates), male hypogonadotropic hypogonadism, and cryptorchidism. Off-label: low-dose HCG (500 IU EOD) maintains intratesticular testosterone and testicular size during TRT.
Meta-analyses found no evidence HCG is effective for weight loss.
Cornerstone of fertility treatments and male hormone therapies. Prevents testicular atrophy and infertility during TRT. Side effects may include gynecomastia (via aromatization) and OHSS in women.
Human Growth Hormone (somatotropin) is produced by the pituitary gland to stimulate growth, cell reproduction, and regeneration. GH secretagogues (GHRPs) like GHRP-2, GHRP-6, and Ipamorelin stimulate the body's own HGH release.
Direct effects: HGH binds to target cell receptors (e.g., adipocytes) to stimulate triglyceride breakdown. Indirect effects: Stimulates IGF-1 production in liver and other tissues — IGF-1 promotes growth, protein synthesis, and inhibits cell death.
Secretagogues work by suppressing somatostatin (the GH inhibitor) while stimulating release — a dual action producing potent pulsatile HGH release. Combining GHRP + GHRH analog produces synergistic effect.
HGH release peaks during puberty and declines with age. Secretagogues consistently stimulate GH secretion dose-dependently and increase circulating IGF-1. Response varies with age — increases from birth to puberty, decreases after the 6th decade.
Newer analogs (GHRP-3) are being studied for endothelial dysfunction and insulin resistance.
Pulsatile HGH maintains body composition (muscle growth, fat breakdown), bone density, tissue repair, and immune function. Age-related decline is associated with decreased muscle mass, increased body fat, and reduced energy.
Long-term risks of secretagogue use include effects on glucose metabolism, fluid retention, and joint pain.
KLOW combines four peptides — KPV, BPC-157, TB-500, and GHK-Cu — into one formulation. Designed for synergistic effects across multiple phases of the repair process: inflammation, vascularization, cell migration, and tissue reconstruction.
1. Anti-inflammatory (KPV): Inhibits NF-κB, suppressing IL-6 and TNF-α.
2. Vascular (BPC-157): Activates VEGF pathway for angiogenesis.
3. Migratory (TB-500): Regulates actin polymerization for cell migration.
4. Reconstruction (GHK-Cu): Activates fibroblasts for collagen synthesis and modulates thousands of genes.
No clinical trials on the combined KLOW blend. Evidence is extrapolated from individual components: BPC-157 (100+ preclinical studies, Phase II human trial), TB-500 (animal wound/cardiac/muscle models), GHK-Cu (human dermatological studies), KPV (preclinical inflammation models).
Synergy is theoretical — formal toxicological studies on the 4-peptide interaction are lacking.
Side effects generally mild — temporary redness or irritation at injection site.
MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is encoded by the mitochondrial genome. It acts as a hormone regulating metabolic homeostasis, particularly in response to metabolic stress. Considered a myokine — produced by and released from muscle during exercise.
Regulates cellular energy metabolism and enhances insulin sensitivity via the folate-AICAR-AMPK pathway. By inhibiting the folate cycle, leads to AICAR accumulation → potent AMPK activation → increased glucose uptake and fatty acid oxidation.
Can translocate from mitochondria to cell nucleus under stress to regulate antioxidant gene expression. Also functions as a physiological myostatin inhibitor, promoting muscle maintenance and growth.
Animal studies show MOTS-c prevents age-related and diet-induced insulin resistance/obesity and enhances physical performance. Human studies found positive correlation between circulating MOTS-c levels and lower-body muscle strength and power.
Plasma MOTS-c increases in response to acute exercise. First human clinical trials are underway.
Links mitochondrial function to whole-body metabolism. Helps the body adapt to metabolic stress by improving glucose utilization and cellular resilience. Exercise-mimetic properties generate interest for type 2 diabetes, obesity, and sarcopenia.
Nicotinamide adenine dinucleotide (NAD+) is a critical coenzyme found in all living cells. Central to metabolism and acts as a key signaling molecule. NAD+ levels decline significantly with age, linked to the progression of many age-related diseases.
Redox coenzyme: Essential electron carrier in glycolysis and TCA cycle → drives ATP production in mitochondria.
Co-substrate for: Sirtuins (regulate gene expression, DNA repair, stress resistance), PARPs (DNA repair — can severely deplete NAD+ when damage is extensive), and CD38 (immune cell enzyme, a major driver of age-related NAD+ decline).
Preclinical research: restoring NAD+ improves mitochondrial function, enhances DNA repair, reduces inflammation, and protects against diabetes, neurodegeneration, and cardiovascular disease.
Human trials focus on precursors NMN and NR. Initial pilot: 250mg NMN is safe. Study in overweight prediabetic postmenopausal women: NMN improved muscle insulin sensitivity.
NAD+ decline with age is a central feature of aging — decreased cellular function, increased disease susceptibility. NAD+-boosting strategies: exercise, caloric restriction, and supplementation with NMN/NR.
Goal: replenish cellular NAD+ pool to support energy metabolism, cellular repair, and resilience against aging stressors.
Retatrutide is a novel, investigational synthetic peptide being developed for obesity and type 2 diabetes. It is a single-molecule triple agonist that simultaneously activates three key metabolic hormone receptors: GLP-1, GIP, and Glucagon. Engineered from a GIP peptide backbone with a C20 fatty diacid moiety, extending its half-life to ~6 days for once-weekly dosing.
GIP Receptor: Most potent at GIPR — enhances glucose-dependent insulin secretion and reduces fat deposition via lipid metabolism.
GLP-1 Receptor: Enhances insulin secretion, slows gastric emptying, and promotes satiety by acting on brain appetite centers → reduced caloric intake.
Glucagon Receptor: Increases energy expenditure and thermogenesis, modulates hepatic glucose production and lipid mobilization.
Combined triple mechanism produces weight loss through both reduced energy intake and increased energy expenditure, with improved glycemic control.
Phase 2 (NEJM): 48 weeks of once-weekly Retatrutide in participants with obesity (no diabetes):
• 12mg protocol: Average weight reduction of 24.2%
• 8mg & 12mg: 100% of participants achieved ≥5% weight reduction
• Type 2 diabetes cohort: 12mg → 16.9% weight reduction over ~8 months
Metabolic improvements: HbA1c reduced 1.3–2.0%. 72% with prediabetes reverted to normal glucose. In NAFLD substudy, 9/10 patients achieved liver fat normalization at highest protocols.
Most common adverse events: GI-related (nausea, diarrhea, vomiting) — mild to moderate, mitigated by protocol titration.
Body Composition: Marked reductions in body weight, BMI, and waist circumference.
Metabolic Health: Improved glycemic control (lower HbA1c, fasting glucose), significant reductions in systolic and diastolic blood pressure.
Cardiovascular: Improved lipid profiles (reduced LDL-C, triglycerides). Concentration-dependent heart rate increase observed, peaking ~24 weeks before declining.
Potent effect on reversing ectopic liver fat deposition — a key driver of metabolic disease. Safety profile similar to other nutrient-stimulated hormone therapies.
Selank is a synthetic heptapeptide derived from the immunomodulatory peptide tuftsin. Developed in Russia for anxiolytic (anxiety-reducing) and nootropic (cognitive-enhancing) properties. Approved in Russia for GAD; not FDA-approved.
GABAergic modulation: Positive allosteric modulator of GABA-A receptors — anxiolytic without sedation, cognitive impairment, or dependence.
Monoamine regulation: Upregulates serotonin metabolism, stabilizes dopamine and norepinephrine. Neurotrophic: Rapidly increases BDNF expression in the hippocampus. Enkephalin protection: Inhibits enkephalin-degrading enzymes.
RCT comparing Selank to benzodiazepine medazepam for GAD: equivalent anxiolytic efficacy but superior side effect profile — no sedation or cognitive impairment. Clinical studies confirmed anxiety symptom improvement via nasal spray.
Evidence supports nootropic effects: enhanced attention, learning capacity, and cognitive performance under stress.
Non-sedating anxiolytic and cognitive enhancer. Reduces anxiety while simultaneously improving mental clarity. Stabilizes mood, reduces stress effects, and supports learning and memory.
No evidence of sedation, amnesia, physical dependence, or withdrawal symptoms in clinical studies. Classified as research chemical in US/EU.
SLU-PP-332 is an estrogen-related receptor alpha (ERRα) agonist designed to mimic the metabolic effects of exercise. Often studied in the context of increasing endurance capacity and boosting metabolic rate without physical exertion.
Directly binds to and activates ERRα, a nuclear receptor that regulates genes involved in mitochondrial biogenesis, fatty acid oxidation, and oxidative phosphorylation. This shifts the cellular metabolic program to mimic an endurance-trained state.
Preclinical studies in mice show profound increases in treadmill running capacity and energy expenditure. Subjects treated with SLU-PP-332 gained less weight and body fat on high-fat diets compared to controls.
By mimicking the transcriptional changes of aerobic exercise, SLU-PP-332 promotes fat oxidation and endurance. This makes it an area of intense interest for combating obesity, metabolic syndrome, and muscle disuse atrophy.
SS-31 (also known as Elamipretide or Bendavia) is a cell-permeable peptide that targets the inner mitochondrial membrane. It is extensively researched for its ability to restore mitochondrial function and reduce oxidative stress.
Selectively binds to cardiolipin on the inner mitochondrial membrane, stabilizing mitochondrial structure and optimizing electron transport chain efficiency. This directly reduces the production of reactive oxygen species (ROS) and improves ATP production.
Has been investigated in clinical trials for heart failure, primary mitochondrial myopathy, and ophthalmic diseases. Strongly protective in ischemia-reperfusion injury and slows age-related muscular and cognitive decline in animal models.
Acts upstream of traditional antioxidants by preventing excessive ROS formation at the source without interfering with necessary physiological ROS signaling. Crucial for tissues with high energy demands like the heart, brain, and skeletal muscle.
Bacteriostatic Water (BAC Water) is sterile water containing 0.9% benzyl alcohol. It is the gold standard diluent used to reconstitute lyophilized (freeze-dried) research peptides and multi-use vials.
The addition of 0.9% benzyl alcohol acts as an antimicrobial preservative. This prevents the growth of most bacteria, enabling the safe storage and repeated use of reconstituted peptide solutions over several weeks.
Compared to sterile water for injection (which must be discarded after a single use), BAC Water allows vials to be safely accessed multiple times. Vials diluted with BAC Water generally remain sterile for 28 days when refrigerated.
Proper reconstitution prevents premature degradation of peptides. Reconstituted solutions should be stored in the refrigerator (2-8°C) to maintain stability. Never shake reconstituted vials vigorously; swirl gently to dissolve.
Tesamorelin is a synthetic GHRH analog and FDA-approved prescription medication for reducing excess visceral adipose tissue (VAT) in HIV-infected patients with lipodystrophy. Distinct from exogenous GH as it preserves the body's natural feedback loops.
Binds to and activates GHRH receptors on the pituitary gland, stimulating pulsatile endogenous GH release. This preserves natural feedback loops unlike direct GH administration. The released GH stimulates liver IGF-1 production, leading to net lipolysis — particularly in visceral fat depots.
Phase 3 trials: 2mg daily produced 15% VAT decrease over 26 weeks (vs 5% increase placebo). Associated with decreased triglycerides and improved glucose homeostasis. Reduced hepatic fat in NAFLD trial.
Exploratory analyses suggest improved muscle quality — increased skeletal muscle area, decreased muscle fat infiltration.
Targeted therapy for visceral fat reduction. By stimulating endogenous GH, effectively reduces harmful fat around internal organs — a major cardiovascular/diabetes risk factor.
Side effects: injection site reactions, arthralgia, peripheral edema. Contraindicated with active malignancy. Being researched for non-HIV visceral obesity and NAFLD.
67 peer-reviewed sources cited across all research profiles.
This report is for research and educational purposes only. All 10KITSM products are strictly for laboratory research and in-vitro testing. Not for human or veterinary use. None of the peptides described herein are approved by the FDA for anti-aging, performance enhancement, or therapeutic use unless specifically noted. Always consult qualified researchers and review current regulatory guidelines.